• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

纳洛酮醇的药理学特性:体外和体内研究。

Pharmacological characterization of naloxegol: In vitro and in vivo studies.

机构信息

Department Translational Medicine, St. Anna University Hospital, University of Ferrara, Ferrara, Italy.

Department of Neuroscience and Rehabilitation, Section of Pharmacology, University of Ferrara, Ferrara, Italy; LTTA Laboratory for Advanced Therapies, Technopole of Ferrara, Ferrara, Italy.

出版信息

Eur J Pharmacol. 2021 Jul 15;903:174132. doi: 10.1016/j.ejphar.2021.174132. Epub 2021 Apr 30.

DOI:10.1016/j.ejphar.2021.174132
PMID:33933466
Abstract

Opioid-induced constipation is the most prevalent adverse effect of opioid drugs. Peripherally acting mu opioid receptor antagonists (PAMORAs), including naloxegol, are indicated for the treatment of opioid-induced constipation. The aim of this study was the in vitro and in vivo pharmacological characterization of naloxegol in comparison with naloxone. In vitro experiments were performed to measure calcium mobilization in cells coexpressing opioid receptors and chimeric G proteins and mu receptor interaction with G protein and β-arrestin 2 using bioluminescence resonance energy transfer. In vivo experiments were performed in mice to measure pain threshold using the tail withdrawal assay and colonic transit using the bead expulsion assay. In vitro, naloxegol behaved as a selective and competitive mu receptor antagonist similarly to naloxone, being 3-10-fold less potent. In vivo, naloxone was effective in blocking fentanyl actions when given subcutaneously (sc), but not per os (po). In contrast, naloxegol elicited very similar effects with sc or po administration counteracting in a dose dependent manner the constipating effects of fentanyl without interfering with the fentanyl mediated analgesia. Thus, a useful PAMORA action could be obtained with naloxegol both after po and sc administration.

摘要

阿片类药物引起的便秘是阿片类药物最常见的不良反应。外周作用型μ阿片受体拮抗剂(PAMORAs),包括纳洛酮,被用于治疗阿片类药物引起的便秘。本研究的目的是比较纳洛酮和纳洛格罗在体外和体内的药理学特性。在体外实验中,通过测量共表达阿片受体和嵌合 G 蛋白的细胞中钙动员和使用生物发光共振能量转移测量μ受体与 G 蛋白和β-arrestin 2 的相互作用,来评估纳洛酮和纳洛格罗的作用。在体内实验中,通过尾巴撤退试验测量疼痛阈值,通过珠子排出试验测量结肠转运。在体外,纳洛格罗与纳洛酮一样,表现为选择性和竞争性μ受体拮抗剂,效力低 3-10 倍。在体内,纳洛酮经皮下(sc)给药可有效阻断芬太尼的作用,但经口服(po)给药无效。相比之下,纳洛格罗以剂量依赖性方式发挥类似的作用,对抗芬太尼的致便秘作用,而不干扰芬太尼介导的镇痛作用。因此,纳洛格罗经 po 和 sc 给药都可获得有用的 PAMORA 作用。

相似文献

1
Pharmacological characterization of naloxegol: In vitro and in vivo studies.纳洛酮醇的药理学特性:体外和体内研究。
Eur J Pharmacol. 2021 Jul 15;903:174132. doi: 10.1016/j.ejphar.2021.174132. Epub 2021 Apr 30.
2
Pharmacological Profile of Naldemedine, a Peripherally Acting -Opioid Receptor Antagonist: Comparison with Naloxone and Naloxegol.那洛肽的药理学特征:一种外周作用阿片受体拮抗剂:与纳洛酮和纳洛酮乙二醇的比较。
J Pharmacol Exp Ther. 2020 Jun;373(3):438-444. doi: 10.1124/jpet.119.264515. Epub 2020 Mar 13.
3
Pharmacologic Profile of Naloxegol, a Peripherally Acting -Opioid Receptor Antagonist, for the Treatment of Opioid-Induced Constipation.纳洛西戈,一种外周作用的μ-阿片受体拮抗剂,用于治疗阿片类药物引起的便秘的药理特性。
J Pharmacol Exp Ther. 2017 May;361(2):280-291. doi: 10.1124/jpet.116.239061. Epub 2017 Mar 23.
4
Insights on efficacious doses of PAMORAs for patients on chronic opioid therapy or opioid-naïve patients.关于慢性阿片类药物治疗患者或阿片类药物初治患者的 PAMORA 有效剂量的见解。
Neurogastroenterol Motil. 2018 May;30(5):e13250. doi: 10.1111/nmo.13250. Epub 2017 Nov 9.
5
Naloxegol for managing opioid-induced constipation.纳洛西戈用于治疗阿片类药物引起的便秘。
JAAPA. 2017 Sep;30(9):51-53. doi: 10.1097/01.JAA.0000522146.29435.c7.
6
Naloxegol for opioid-induced constipation in patients with noncancer pain.纳洛酮治疗非癌症疼痛患者的阿片类药物诱导性便秘。
N Engl J Med. 2014 Jun 19;370(25):2387-96. doi: 10.1056/NEJMoa1310246. Epub 2014 Jun 4.
7
Naloxegol: A Novel Therapy in the Management of Opioid-Induced Constipation.纳洛西戈:治疗阿片类药物引起的便秘的一种新型疗法。
Am J Hosp Palliat Care. 2016 Nov;33(9):875-880. doi: 10.1177/1049909115593937. Epub 2015 Jul 6.
8
Novel Oral Therapies for Opioid-induced Bowel Dysfunction in Patients with Chronic Noncancer Pain.慢性非癌性疼痛患者阿片类药物所致肠道功能障碍的新型口服疗法
Pharmacotherapy. 2016 Mar;36(3):287-99. doi: 10.1002/phar.1711. Epub 2016 Mar 6.
9
Naloxegol: a review of its use in patients with opioid-induced constipation.纳洛酮:用于治疗阿片类药物引起的便秘的研究进展。
Drugs. 2015 Mar;75(4):419-25. doi: 10.1007/s40265-015-0357-2.
10
Cardiovascular Safety of the Selective μ-Opioid Receptor Antagonist Naloxegol: A Novel Therapy for Opioid-Induced Constipation.选择性μ-阿片受体拮抗剂纳洛西戈的心血管安全性:一种治疗阿片类药物引起的便秘的新疗法。
J Cardiovasc Pharmacol Ther. 2018 Jul;23(4):309-317. doi: 10.1177/1074248418760239. Epub 2018 Mar 4.

引用本文的文献

1
Chronic constipation in Parkinson's disease: clinical features and molecular insights on the intestinal epithelial barrier.帕金森病中的慢性便秘:肠道上皮屏障的临床特征与分子见解
Ann Gastroenterol. 2024 Jan-Feb;37(1):22-30. doi: 10.20524/aog.2023.0851. Epub 2023 Dec 23.
2
Functional selectivity of EM-2 analogs at the mu-opioid receptor.EM - 2类似物在μ阿片受体上的功能选择性
Front Pharmacol. 2023 Feb 24;14:1133961. doi: 10.3389/fphar.2023.1133961. eCollection 2023.
3
Peripherally restricted transthyretin-based delivery system for probes and therapeutics avoiding opioid-related side effects.
外周受限转甲状腺素蛋白基递药系统,用于避免阿片类药物相关副作用的探针和治疗药物。
Nat Commun. 2022 Jun 23;13(1):3590. doi: 10.1038/s41467-022-31342-z.